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PERCEPTIONS OF HIV-POSITIVE KIDNEY DONATIONS TO HIV-POSITIVE  
 
RECIPIENTS 
 
JULIE STOMEL 
ABSTRACT 
Background 
Kidney transplantation is the preferred standard of care for patients who have both end 
stage renal disease (ESRD) and human immunodeficiency virus (HIV) infection.  The 
first successful kidney transplant was done in 1954 and the first case of HIV/AIDS 
occurred in 1981. Until recently, HIV-positive patients who required an organ transplant 
received an HIV-negative organ because it was illegal to use HIV-positive organs in 
transplants in the United States.  The HIV Organ Policy Equity (HOPE) Act was signed 
in 2013 and legalized the use of HIV-positive donor organs in organ transplants.  The 
first of these transplants was completed in March 2016 with good results.   
Literature review 
Renal transplants have lower mortality than dialysis. HIV damages the kidney in multiple 
ways, including HIV associated nephropathy and HIV immune complex kidney disease, 
putting HIV patients at higher risk of ESRD. Studies from before the utilization of anti-
retroviral therapy show that transplantation of HIV infected blood or organs do not cause 
failure of the transplanted organ. However, in 1997 most surgeons would not transplant 
kidneys to HIV-infected individuals. Success of antiretroviral therapy has allowed HIV 
patients to live longer, but patients experience complications including end organ 
damage. Providing transplants to ESRD patients with HIV infection has been preferred 
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treatment since 2010. Due to improvements in both HIV and transplant science, 
transplant specialists today are likely to accept HIV-positive organs to HIV-positive 
transplant recipients. 
Proposed project 
The proposed study is a survey of United States transplant professionals to determine 
their perceptions about these transplants.  Researchers will collect data in the form of 
Likert scales as well as open-ended responses.  The survey will also collect demographic 
information about surveyors.  Investigators will then analyze the collected data for 
professional knowledge of the legal change, perceptions of efficacy and safety, and 
concerns.  Researchers will analyze the data both as a whole and divided by demographic 
subgroups.   
Conclusions 
To date, there has been no study that has assessed at the attitudes of the medical 
community involved in these transplants.  This study is unique in that it attempts to 
obtain the perceptions and concerns the transplant specialists have about HIV-positive 
donor organs to HIV-positive transplant recipients. 
Significance 
The data from this study will help to establish what opinions are at this time, to determine 
if there are any regional discrepancies that may affect patient access to care, and to 
determine the concerns of transplant specialists at this time.   
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INTRODUCTION 
Background 
Organ transplant is often a treatment option for patients with end stage renal disease 
(ESRD).  Kidney transplantation is the process in which a kidney is surgically removed 
from either a living person or deceased person.  The kidney is implanted into the 
recipient’s abdomen, and if successful, allows the recipient to have a functioning kidney.  
This saves the patient from renal failure and avoidance of dialysis or reduces time on 
dialysis.  The recipient takes immunosuppressive medications both prior to and after the 
surgery to prevent loss of the new kidney38.  According to the 2013 Organ Procurement 
and Transplantation Network/Scientific Registry of Transplant Recipients (OPTN/SRTR) 
Annual Data Report, in 2013 there were 16,901 adult kidney transplants completed in the 
United States and there were 96,607 adults on the transplant list waiting for a kidney as 
of December 31, 201338.   
Kidney transplants become more complicated if the patient who needs the kidney 
is infected with Human Immunodeficiency Virus (HIV).  Standard of care for treatment 
of HIV infection requires decades long therapy with antiretroviral medications18.  Patients 
who take the antiretroviral medications, called highly active antiretroviral therapy 
(HAART), are typically successful at controlling the HIV infection2,18.  However, 
HAART therapy does not rid the patient of the infection and is not a cure 2, 18.   
Poor kidney function is one of the most common complications of HIV infection in the 
HAART era, with up to 30% of patients having abnormal renal function58.  The causes of 
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kidney disease in HIV patients vary and include non-HIV related causes such as 
hypertension and diabetes associated nephropathy24, 32, 58, 65.   
However, HIV infection itself can cause kidney damage.  HIV associated 
nephropathy is a severe form of glomerulonephritis that develops in 5-10% of patients on 
HAART medications33.  HIVAN is the third leading cause of ESRD in African American 
males age 20-64 in the United States8, 24.  HIVAN can lead to ESRD within 6 months49.  
There is also HIV immune complex kidney disease (HIVICK), which is more common in 
non-African descendants23.  Additionally, some HAART medications have nephrotoxic 
effects that can further cause kidney disease2,8,9,18,19,24,36,49,54,58,67.  Overall, HIV infection 
is a leading cause of ESRD requiring the need for renal replacement therapy. 
There are two main options for renal replacement therapy: dialysis and organ 
transplant.  Until 2005, transplantation was often not an option for HIV-positive patients 
in the United States for fear that the necessary immunosuppression required for 
transplantation would cause increased morbidity and mortality33.  However, studies 
published in 2005 show that HIV-positive kidney recipients can achieve survival rates 
similar to HIV-negative patients33, 49.   
Although HIV-positive patients are able to accept organs, HIV-positive patients 
were not able to donate organs until 2013 when the HOPE Act was approved.  Therefore, 
prior to the HOPE act HIV-positive organs could not be used in organ transplants.  The 
new law allows HIV-positive donor to HIV-positive recipient organ transplants in the 
United States.  The first of these transplants was done in March 2016. 
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Statement of the Problem 
The HOPE Act was first approved in November 2013 and updated in November 2015.  
The first HIV-positive to HIV-positive organ transplants in the United States were 
completed in the spring of 2016.  There has been no analysis into what transplant 
surgeons, transplant nephrologists, and transplant PAs’ perceptions are about HIV-
positive donor organs to HIV-positive organ transplant recipients in the United States.   
It is important to know the transplant specialists’ perspective of HIV-positive 
donor to HIV-positive recipient transplants at this point of time for multiple reasons.  
First, it is important to establish a baseline for future researchers to understand the 
attitudes and perspectives of these specialists at the beginning of the HOPE era.  Be it a 
failure or a success, future scholars will want to know what the community is thinking at 
this moment.  Additionally, the perceptions of specialists can help point us in a direction 
to spend funding.   
The study proposed will yield a way to determine the perceptions of transplant 
surgeons, transplant nephrologists, and transplant surgical physician assistants on the 
topic of HIV-positive to HIV-positive organ donations. 
  
 Hypothesis 
Transplant surgeons, transplant nephrologists, and transplant physician assistants will be 
aware of the legality of HIV-positive donor organ to HIV-positive recipient transplants, 
and perceive HIV-positive donor organ to HIV-positive organ recipient transplants as 
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effective and an ethical treatment option for their patients on a qualitative survey of 
perceptions. 
 
Objectives and specific aims  
HIV-positive donor organ donation to HIV-positive recipient in the United States is a 
new endeavor, with the first surgery occurring in March 2016.  There is no data about the 
beliefs of the teams completing these transplants.  The overall goal in conducting this 
research is to understand the perspective of transplant specialists involved in HIV-
positive to HIV-positive organ transplants. 
 
Specific aims of this study are to:  
1. Establish if transplant specialists are aware of the legislative change that makes 
HIV-positive donor organs to HIV-positive organ transplant recipients legal in the 
United States 
2. Determine if transplant specialists believe HIV-positive to HIV-positive 
transplants will be safe and effective treatment options for their patients 
3. Understand the concerns that transplant specialists have about HIV-positive to 
HIV-positive transplants 
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REVIEW OF THE LITERATURE 
Overview 
 
Renal transplants 
 
To fully understand transplantation of HIV-positive kidneys into HIV-positive recipients, 
it is important to first appreciate treatment of end stage renal disease via renal transplants 
and HIV infection individually (See figure 1, page 6 for timeline).  On April 3, 1933 
Yurii Voronoy in Ukraine completed the first human kidney allotransplant39.  He took a 
six-hour anoxic cadaver kidney and transplanted it into the thigh of the recipient39.  
Although the patient died after 2 days secondary to ABO incompatibility, Voronoy is 
credited by future transplant surgeons as having completed the first human 
allotransplant39.   
Further research in renal transplantation occurred in both humans and animals.  
The next significant event was the first successful renal transplantation in 195441.  A 24-
year-old male named Richard Herrick was transferred to Peter Bent Brigham Hospital 
with chronic glomerulonephritis after unsuccessful treatment with conservative therapy41.  
Herrick had an identical monozygotic brother, and after testing for 21 identical antigens 
for blood subgroups and successful skin grafting between the twins to confirm 
monozygoticity, the surgeons decided that they were good candidates for renal 
transplantation41.  On December 23rd, 1954, the transplant was completed with survival of 
both brothers and the transplanted kidney41.  This transplant proved that  
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“homotransplantation of the kidney in man is at least a technically feasible procedure” 
and provided proof of concept of homotransplantation 41.  Richard Herrick did not take 
any immunosuppressive medications62 and lived for 8 years after his surgery before death 
from myocardial infarction unrelated to the surgery46.  This operation is considered the 
first successful kidney transplant41. 
Figure 2- Timeline of select important events in the history of renal replacement therapy and HIV/AIDS 
Timeline of select important events in the history of renal 
replacement therapy and HIV/AIDS 
Figure 1- Timeline of select important events in the history of renal replacement therapy and HIV/AIDS. See 
text for full details and additional events. 
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In 1961, the first successful living donor kidney transplant between non-siblings 
occurred, setting the way for future transplants between people who are not related62.  In 
1962, the immunosuppressive drug azathioprine was introduced, decreasing the acute 
graft rejection rate62.  Also in 1962, cadaveric donor transplants occurred successfully for 
the first time (using azathioprine and actinomycin for immunosuppression), opening up 
new sources of organs for patients62.  Renal transplants were on the path to being the gold 
standard treatment for end stage renal disease. 
Dialysis is the alternative treatment for end stage renal disease.  Dialysis 
machines were first constructed in 1943, and were initially used for acute renal failure7.  
Patients were first treated for chronic renal failure via intermittent hemodialysis in 1960 
at the University of Washington7.  Three of the first four patients survived the first year 
on intermittent hemodialysis (and would live for more than 10 years), making it a 
success7.  However, funding was a problem and initially severely limited the number of 
patients that could have dialysis treatments7.  In 1970, a report with 170 patients studied 
showed 90% survival at 1 year and 61% survival at 5 years7.  On October 30, 1972 
President Nixon signed a bill that established Medicare entitlement for patients needing 
dialysis or transplantation, making renal replacement treatment available and affordable 
to all renal failure patients7. 
As surgeons gained experience in transplanting kidneys, many studies came out 
comparing dialysis and transplantation.  A systematic review published in 2011 that 
analyzed 110 studies and 1,961,904 patients with renal failure revealed renal transplants 
are associated with significantly lower mortality and significantly increased quality of life 
	 	 	
	
compared to chronic dialysis69.  From the first successful transplant in 1954 to the 
systematic review published in 2011, transplantation science has become the gold 
standard in treating end stage renal disease for those fortunate enough to receive a 
transplant.   
 
Human Immunodeficiency Virus / Acquired Immune Deficiency Syndrome 
 
HIV/AIDS was a public health emergency in the United States and other developed 
nations from its discovery until the success of antiretroviral medications, and is still an 
emergency in developing regions21.  Retrospectively, the first cases of what is now 
known as the AIDS epidemic was published on June 5, 1981 in a US Center for Disease 
Control and Prevention (CDC) Morbidity and Mortality Weekly Report that highlighted 
five previously healthy young homosexual men who were diagnosed with Pneumocystis 
carinii pneumonia, indicating severe immunodeficiency12.  By the end of 1981, there 
were 270 reported cases of severe immune deficiency among homosexual men, with 121 
deaths29.  On September 24, 1982, the CDC used the term Acquired Immune Deficiency 
Syndrome (AIDS) for the first time, and defined AIDS as “a disease at least moderately 
predictive of a defect in cell-mediated immunity, occurring in a person with no known 
case for diminished resistance to that disease”14.  In March 1983, the CDC released a 
report that suggested AIDS may be caused by an infectious agent that is transmitted via 
sexual contact and blood products13.  Because of the nature of its transmission, the CDC 
was able to give recommendations to prevent the spread of HIV for the first time.  On 
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May 20th, 1983, Dr. Francoise Barre-Sinoussi and her team isolated the retrovirus that 
they proposed and was later proven to cause AIDS5.  The first antiretroviral drug 
zidovudine (AZT) was approved in 198767.  In 1988, HIV-positive organ donations were 
banned which made HIV infection the only exclusion criteria written into the transplant 
legislation8.   
In 1992, AIDS was the number one cause of death for US men ages 25-4414 and 
in 1994 AIDS became the leading cause of death of all Americans ages 25-4459.  In June 
1995 the first protease inhibitor, Saquinavir, was approved by the FDA and is now 
considered the start of the HAART era3.  In 1997, HAART therapy was the standard of 
care for HIV patients43, and the first substantial decline in AIDS-related deaths was 
reported in British Columbia, Canada30.   
 
Kidney Disease and HIV 
 
Renal disease is one of the most common complications of HIV infection, with abnormal 
kidney function in up to 30% of HIV patients58.  HIV affects the kidney in multiple ways.  
Both diabetes and hypertension are more common in HIV patients than the general 
population, and both can lead to chronic kidney disease24,  32,  58, 65.  Acute renal failure is 
also more common in HIV patients than in the general population, with underlying CKD, 
HIV infection, and HCV infection as risk factors58.  Additionally, some antiretroviral 
agents are nephrotoxic2,8,9,18,19,24,36,49,54,58,67.  For example, tenofovir is a first-line HAART 
agent that has a small nephrotoxic effect that can overtime cause clinically significant 
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kidney damage18.  Therefore, HIV patients are at higher risk for renal disease than the 
general population18. 
There are two common types of chronic kidney disease found in HIV patients that 
are not found in non-HIV patients, called HIV-associated nephropathy (HIVAN) and 
HIV immune complex kidney disease (HIVICK).  HIVAN is caused by “direct viral 
infection of kidney cells (particularly the visceral epithelial cells of the glomerulus and 
the tubular epithelial cells) and it is more common in patients with high plasma HIV-
RNA viral load”15.  Expression of the HIV transgene induces dedifferentiation as well as 
proliferation of glomerular epithelial cells while also impairing cytokinesis in tubular 
epithelial cells4.  This causes a collapsing form of focal sclerosing glomeruloscelrosis that 
also has interstitial inflammation and microcystic tubular dilation34.  HIVAN affects 
mainly patients of sub-Saharan African descent24  and is the 3rd most common etiology of 
renal disease in African Americans aged 20-64 after diabetes and hypertension24.  
Overall, HIVAN occurs in approximately 10% of all patients with HIV24 and is 
considered the most aggressive HIV-related renal disease24 because it can progress to 
ESRD within weeks to months24, making it the most common cause of renal failure in 
HIV-1-seronegative patients4. 
 HIVICK occurs when HIV infection causes deregulation of the immune system 
and causes “increasing gamma globulin contributing to immune complex formation”23.  
HIVICK patients have lupus-like lesions on renal histology without other evidence of 
lupus23.  Patients present with various renal disease manifestations depending on where 
the lesions are, but proteinuria and hematuria are common findings23.  HIVICK appears 
	 	 	
		
to be more common in patients with non-African descent, and prognosis is better than for 
HIVAN23. 
Despite high prevalence of renal failure amongst HIV patients, a survey 
conducted in the Spring of 1997 and subsequently published in the journal 
Transplantation, concluded that the “majority (88%) of US transplant centers will not 
transplant kidneys to HIV-infected patients with end-stage renal disease, even if their 
infection is asymptomatic”61.  The timing of this survey is significant because in 1997, 
HAART therapy became standard of care for treating HIV-infected patients43 and is when 
for the first time prognosis started to improve30,35.  However, “transplantation was 
thought to be contraindicated [by surgeons] because of the poor prognosis militated 
against using scarce organs for HIV-infected people, and it was feared that allogenic 
stimulation and immunosuppressive drugs (used to prevent rejection) might accelerate the 
patient’s demise”61.  As opposed to the surgeons, the authors of the study suggest that 
HIV-infection is “not a valid reason for automatically excluding” from transplantation61.  
Thus, from the beginning of the HAART era, HIV-positive transplantation had both 
opponents and proponents.   
Between 1998 and 2003, the overall perception of HIV in developed countries 
changed from “a terminal to chronic illness [and] accordingly, transplantation in HIV-
infected patients [had] been initiated at a handful of centers”28.  A study published in 
American Journal of Transplantation in 2005 regarding the perceptions of surgeons of 
transplantation in HIV, Hepatitis B (HBV), and Hepatitis C (HCV) infected patients 
showed that surgeons had greater fear of becoming infected with HIV than with HBV or 
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HCV, and that most surgeons still considered HIV infection to be a contraindication to 
transplantation28.  However, surgeons surveyed in this study believed that HIV-positive 
patients would receive benefit receiving a transplant28 versus the 1998 study when 
surgeons were fearful the transplant would hasten the patient demise61.  It is important to 
note that despite the surgeons’ fear, there were HIV-positive transplants being done in 
200328. 
Much progress has been made in prevention and treatment of HIV since the 
1980s.  HIV infection incidence has been decreasing, down from 3.3 million in 2002 to 
2.3 million in 201236.  However the prevalence of HIV infection is increasing worldwide 
because patients are living longer with the infection36.  Globally, AIDS-related deaths 
peaked in 2005 at 2.3 million and had decreased to 1.6 million by 201236.  Much of this 
decrease is due to decreased heterosexual transmission36.  In 2012, an estimated 35.3 
million people were living with HIV36.  Advances in both treatment and prevention have 
even lead some to envision a future where “HIV infections and deaths from AIDS are 
rare”21. 
In the past 22 years, since AIDS was noted to be the leading cause of death 
among Americans ages 25-44, HIV infection has gone from a “modern day plague”21 to a 
chronic disease.  This success is due to highly active antiretroviral therapy (HAART)8 
which is the practice of using multiple drugs that target the virus at different enzymes 
required for its replication2,43.  Patients who have access to and who take their prescribed 
HAART regimen for decades can expect improved health and prolonged life compared to 
those who do not take HAART medications18.  Patients who start taking HAART in their 
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20s can live into their 70s57.  However, new complications have come forth, underscoring 
the disease portion of the phrase ‘chronic disease’18.  Several inflammation-associated 
and immunodeficiency complications arise in HAART treated HIV patients, such as 
cardiovascular disease25, kidney disease, liver disease, and cancer18.  For example, HIV 
infected adults had a 50% increased risk of having a myocardial infarction as a non-
infected adult when traditional risk factors were controlled for18, 25.  Additionally, the 
antiretroviral agents have toxic side effects that build up after decades of use that can 
cause clinically important end organ damage18.  Together, all these complications of 
having chronic HIV infection are termed non-AIDS morbidity.  Therefore, while people 
are living longer with HIV on HAART, the antiretroviral medications are not a cure for 
HIV infection and complications do arise. 
Because patients are living longer with HIV infection, organ failure is a problem.  
Organ transplant is a solution, but was only determined definitively to be so for HIV 
patients in the US in 201064.  The first US study published was in 2006 and followed 38 
donor kidney pairs that were transplanted into one HIV-positive patient and one HIV-
negative patient.  In this study there was a non-statistically significant higher patient and 
graft survival in HIV-positive patients at 5 years49.  Adjusted analysis showed HIV was 
not associated with graft loss65.  A more conclusive study was the NIH-sponsored US 
HIV-TR trial published in 2010.  This study looked at 150 HIV-positive patients who had 
kidney transplants between 2003 and 2009.  In this study, “both patient- and graft-
survival rates were high at 1 and 3 years, with no increase in complications associated 
with HIV infection”64.  However, a “higher than expected rejection rate was observed” 
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which is “of serious concern and indicate[s] the need for better immunotherapy”64.  The 
study concluded that, “the major issues encountered in HIV-TR were achieving 
therapeutic, but nontoxic drug levels, a high rejection rate, and future management of 
HCV coinfection.  HIV remained well controlled, and renal transplantation was shown to 
be a viable option and feasible in selected patients” 65.  A follow up study published in 
2015 confirmed these results and concluded that “kidney transplantation should be 
standard of care for well managed HIV-positive patients”54.  Overall, HIV infection is no 
longer a contraindication to kidney transplant, and good patient outcomes have been 
described in numerous studies.   
The question becomes which HIV infected patients are eligible for renal 
transplant.  The Guidelines for Kidney Transplant in Patients with HIV disease written on 
behalf of the British HIV Association and reviewed and endorsed by the British 
Transplantation Society Standards Committee is a set of recommendations used by 
transplant centers, including Boston Medical Center6.  These guidelines suggest that “any 
patient with end stage renal disease is eligible for transplantation if medically fit.  Life 
expectancy of at least five years is considered appropriate before embarking on 
transplantation”6.  The Guidelines also lay out HIV specific inclusion criteria, including 
CD4>200 cells/microliter for at least six months, undetectable HIV viremia (< 50 
copies/ml) for at least 6 months, demonstrable and a stable HAART regimen for > 6 
months, absence of AIDS defining illness following successful immune reconstitution 
after HAART, and available anti-retroviral treatment options in the future6.  HIV-disease 
specific exclusion criteria include documented history of progressive multifocal 
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leukoencephalopathy (PML), extracutaneous Kaposi’s Sarcoma (KS), EBV and HHV8-
related lymphopoproliferative disorders, CD4 count < 200 cells/microliter, persistent HIV 
viremia despite HAART, continuing non-compliance with anti-retroviral therapy, and 
more than three-class HIV resistance and lack of future HIV treatment options6.  The 
guidelines also contain inclusion and exclusion criteria that are not specific to HIV 
infection, include criteria for pre-transplant assessment and vaccinations, and 
immunosuppressant protocols6. 
 
HIV-positive organs for HIV-positive transplant recipients 
 
The first HIV-positive organs intentionally transplanted into HIV-positive patients were 
in South Africa.  In South Africa, like most places in the world, the HIV infection was 
considered an absolute contraindication for organ transplant.  However, unlike other 
places in the world, dialysis in South Africa is only used as a bridge to transplantation 
due to lack of public resources17.  Therefore, HIV-positive renal failure patients in South 
Africa were ineligible for dialysis17 unless they had private insurance, which very few 
South Africans have50.  Because HIVAN is the number one cause of ESRD in South 
Africa, this allocation of resources caused many patients to be “sent home to die”45.  In 
fall 2008, Dr. Elmi Muller “undertook four renal transplantations involving HIV-positive 
recipients and HIV-positive donors” at Groote Schuur Hospital in Cape Town, South 
Africa45.  The transplants involved “two deceased donors who had not received any 
antiretroviral therapy, did not have a history of serious opportunistic infection or cancer, 
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and had normal renal biopsies without evidence of proteinuria”45.  The four initial 
transplants were deemed a success51.  Muller’s initial triumph changed South African 
policy and stopped “the exclusion of HIV-infection persons from the general renal-
transplantation program” in 200944, which allowed “HIV-infected patients to receive 
kidneys from HIV-negative donors or from HIV-positive deceased donors” at Groote 
Schuur Hospital44.  Muller and her team proved that HIV-positive to HIV-positive kidney 
transplants were safe and effective in carefully selected patients44.   
Colleagues in the United States, where transplants using HIV-positive organs 
were still illegal, were watching Muller’s success.  Advocates who wanted to make HIV-
positive transplants legal in the United States knew that knowing an estimated number of 
lives saved per year would be essential when talking to members of congress9.  Because 
UNOS does not track HIV-positive donors, researchers had to look elsewhere for this 
data.  One study estimates that in the United States there would be 500-600 HIV-positive 
donors per year who would be eligible transplant candidates9.  This study utilized the 
Nationwide Inpatient Sample and the HIV Research Network to generate its data9.  A 
second study that looked at a single center and then extrapolated data estimated 
approximately 356 HIV-positive deceased donors each year52.  By utilizing these donors, 
it could help with the current organ shortage and waitlist mortality9, 52.  If a HIV-positive 
patient is willing to accept a HIV-positive organ in the United States, wait time “would 
likely be less than 1 year”63 compared to the excess of 7 years many patients currently 
wait for a deceased donor kidney63.  Furthermore, if all 356-600 HIV-positive organs are 
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used by HIV-positive patients each year, there are more organs available for non-HIV 
patients with ESRD which shortens the overall wait time and decreases overall morbidity.   
In November 2013, the HOPE Act was signed into law in the United States.  It 
mandated that the Secretary of Health and Human Services develop “criteria for the 
conduct of clinical research involving [HIV-positive deceased donor] organs” by 
November 20158.  The final guidelines were published on November 25, 2015.  These 
guidelines state that “the goal of this research is to increase the knowledge about the 
safety, efficacy, and effectiveness of solid organ transplantation (SOT) utilizing HIV-
positive donors in HIV-positive recipients”47.  These final guidelines also updated the 
HOPE Act so to allow living donations, which were previously not addressed47.   
 The current version of the HOPE Act includes eligibility criteria for donors, 
recipients, and transplant hospitals47, 56.  Donors may be either deceased or living47.  If 
deceased, the transplant team must propose a safe antiretroviral regimen for the recipient 
after taking the donor’s drug regimen history47, 56.  If a safe combination is not available, 
the transplant may not continue47, 56.  If the donor is living, that donor must be assessed 
for future risk of kidney disease47.  The living donor must also go through a consent 
process that documents their understanding of “(1) the possibility that the loss of organ 
function resulting from donation could preclude the use of certain antiretroviral drugs in 
the future; (2) the risk of kidney or liver failure in the future; (3) the possibility of 
transmission of occult opportunistic infections to the recipient; and (4) the absence of 
U.S.  experience in HIV-positive to HIV-positive organ transplantation, and thus the 
unpredictable nature of donor and recipient outcomes”42, 47.   
	 	 	
	 18	
As previously discussed, there is recipient eligibility criteria, however the criteria 
written into law is less extensive than what hospitals often use and what was previously 
discussed.  The HOPE Act specifically requires HIV-positive recipients to have CD4+ T 
cell counts >200/uL within 16 weeks prior to transplant, HIV RNA less than 50 
copies/mL and on a stable antiretroviral regimen, no evidence of opportunistic infection, 
and no history of primary central nervous system lymphoma or progressive multifocal 
leukoencephalopathy47, 56.  The transplant team must also be confident that they will be 
able to control the patient’s HIV infection after transplant. 
The criteria for the hospitals preforming the transplants are set to ensure patient  
safety47, 56.  The hospital must be “an established program for the care of individuals 
infected with HIV” 56.  There must also be a study team that has at least a transplant 
surgeon, a transplant physician, and an HIV physician47, 56.  In the past 5 years, the 
transplant physician and HIV physician collectively must have completed 5 transplants of 
HIV-negative organs into HIV-positive patients in the past 4 years47,56.  The hospital must 
provide an individual advocate to the recipient and to the living donor in the case of 
living donor transplants47, 56.   
Currently, all HIV-positive to HIV-positive solid organ transplants “occur under 
IRB-approved protocols” and must follow the many regulations set forth by the National 
Institutes of Health47, 56.  However, in a limited form, the HOPE Act allows HIV-positive 
to HIV-positive organ transplants to occur in the United States for the first time.   
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Much progress has been made in organ transplantation since Yurii Voronoy completed 
the first human kidney allotranspant in 193339.  The next horizon in transplantation is the 
use of HIV-positive organs for HIV-positive patients. 
 
Existing research 
By weaving together pieces of existing research that relate to individual aspects of HIV-
positive to HIV-positive transplants and opinions of transplant specialists about related 
topics, as well as views of patients, the perceptions of transplant specialists concerning 
HIV-positive to HIV-positive organ transplants may begin to become more clear. 
Organs or blood product infected with HIV have been transplanted previously, 
albeit accidentally19, 70.  As previously discussed, the first organ transplant was completed 
in 1954 and the HIV virus discovered in 1983, so the transmission of HIV via organ 
transplant was a concern upon the discovery of the virus70.  A study by Dummer et al 
examined pre- and post-transplant sera from 1043 patients who had organ transplants at 
the University of Pittsburg between 1981 and 198619, before any retroviral drugs were in 
use67.  They found that 25 patients (1.7%) were either HIV-positive at the time of the 
transplant or seroconverted soon afterwards19.  These patients were then followed and 
their clinical course and survival monitored19, 70.  Eleven of the 25 patients were HIV-
positive prior to the transplant19, 70.  Fourteen of the 25 patients seroconverted to HIV-
positive status after the transplant, indicating that either the organ that was transplanted or 
blood products infused during their hospitalization contained the HIV virus19, 70.  Seven 
of these 14 patients were still alive at follow-up of 4.8 +/-1.8 (SD) years (range 2.1-6.6)19, 
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70.  The authors of this study suggest that HIV-positive patients should not be 
automatically excluded from receiving organ transplants19, 70.   
A similar study was completed in the North Italy Transplant Program (NITp) 
when it started screening for anti-HIV antibodies on September 1, 198548.  Data was 
collected on patients with renal transplants between January 1, 1978 and August 31, 
198548 .  When data was published in 1988, there were eight confirmed cases of post-
transplantation seroconversion48.  At time of publication, three of the eight patients had 
died48 .  Of these eight, one died of overt AIDS, one of Karposi sarcoma, and one of 
cerebral hemorrhage without any sign of HIV-related disease48 .  The other five were still 
alive at time of publication48.  Two were on dialysis with HIV related illnesses, indicating 
graft failure48.  The other three had functioning allografts with no signs of HIV 
infection48. 
These two early studies show that even without HAART therapy, which was not 
being used at the time of the studies67, transplantation of HIV infected blood or organs do 
not cause failure of the transplanted organ19, 48, 70.  With the addition of HAART therapy, 
one would expect the results of transplanting HIV-positive organs to be even more 
successful.   
Muller’s team in South Africa was the first to intentionally transplant organs 
infected with HIV44.  Through February 2014, Muller’s team completed a total of 27 
HIV-positive kidney transplants44.  Data published in 2015 showed “the rate of survival 
among the patients was 84% at 1 year, 84% at 3 years, and 75% at 5 years.  The 
corresponding rates of graft survival were 93%, 84%, and 84%” 44.  Furthermore, 
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“rejection rates were 8% at 1 year and 22% at 3 years.  The HIV infection remained well 
controlled, with undetectable virus in [sic] blood after the transplantation”44.  These 
results “compare favorably with reported outcomes in HIV-positive patients who 
received kidneys from HIV-negative donors”44.  However, “rejection rates among HIV-
positive recipients have been reported to be approximately 3 times as high as those 
among HIV-negative recipients.  The reason for this is still unknown”44. 
After the signing of the HOPE Act in November 2015, the first intentional HIV-
positive to HIV-positive transplants were done in the United States in March 2016 by Dr.  
Dory Segev.  In an interview published in the Journal of the American Medical 
Association, Dr. Segev stated the operations “went beautifully.  The issues were nothing 
different from what [they] would normally deal with [when] HIV-positive patients 
receive HIV-negative organs”37. 
Recent studies in other countries have been conducted to see if HIV-positive 
patients would consider donating their organs after their death.  A study in Taiwan 
published in 2016 found that 71.9% of surveyed HIV-positive patients would be willing 
to donate their organs if it were legal to do so in Taiwan35.  A recent United Kingdom 
study of HIV-positive patients found that 62% would donate their organs66.  While there 
is no published US study of HIV-positive patient perspectives, a 2014 study that surveyed 
all volunteering individuals leaving Chicago Department of Motor Vehicle buildings 
found that 90% of participants would likely donate an organ to a needy family member or 
friend and 17% would donate to a stranger 27.   
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The aforementioned study conducted in the United Kingdom surveyed HIV-
positive patients who were attending HIV outpatient clinic for routine follow up66.  These 
patients were also asked about their perceptions of HIV-positive to HIV-positive organ 
donation66.  When asked if they would accept an HIV-positive organ, 55% stated they 
would66.  Of those who would not accept an organ, their main concerns were 
confidentiality, infection, and quality of organ66.  Patients who were infected with HIV 
for longer were less likely to be willing to receive an HIV-positive organ compared to 
those more recently infected66.  This data can be compared to a 2015 study of African 
American hemodialysis patients in Philadelphia that did not look at HIV status and 
concluded 72.3% would accept a living donor kidney transplant (LDKT), and 
unwillingness to accept an organ was associated with patients who experience increased 
recovery time after dialysis, concerns about the donor, and concerns about themselves26.   
When HIV-positive patients in the UK study “were asked whether they would 
accept an organ to stay alive and/or improve quality of life” 66% responded that they 
would66.  This statistic is most applicable to the patients who would receive HIV-positive 
kidney transplants in the United States, because they would otherwise be reliant on 
dialysis and are concurrently dying of end stage renal disease.   
Although HIV-positive organs were not intentionally transplanted in the United 
States until 2016, organs from high infectious risk patients have been transplanted.  These 
organs test negative for disease, but the donor has behavioral risk factors that increase the 
chance that they recently contracted an infection and it is too soon to show up on the 
screening tests55.  These risk factors include, but are not limit to, IV drug use, men who 
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have sex with men, non-sterile tattooing in the past 12 months, or a prison stay for more 
than 72 hours in the last 12 months16.  Infectious risk donors (IRDs) comprise about 9% 
of the deceased donor pool and have a very low incidence of actual infection55.  
Recipients of increased risk donor organs should have post-transplant testing for HIV, 
HBC, and HCV16.  “[S]ignificant variation exists in provider willingness to utilize IRD 
kidneys”55 and patient “attitudes toward transplantation with IRD kidneys were negative 
overall” but “patients reported increased willingness to consider IRD kidney 
transplantation after receiving education” about IRDs55.  Of note, the potential recipients 
questioned in this study did not already have any infectious disease55 . 
Perhaps most akin to HIV-positive to HIV-positive transplants are Hepatitis C 
(HCV) positive donors to HCV-positive recipients.  Kidneys from donors with known 
HCV infection have been transplanted into patients who also have HCV71.  Because 
legislation specifically banned organs infected with HIV20, HCV positive status is not and 
was never a contraindication to organ donation10 .  Although there are risks involved, 
patients with HCV (but not HIV) who receive a HCV-positive kidney transplant have 
better survival rate than remaining on dialysis31.   
The 2015 update to the HOPE Act also permits clinical trials to be done utilizing 
living donors, which was not initially included in the 2013 version of the act47, 56.  
Previous research into HIV-positive patient perceptions of receiving an organ from a 
HIV-negative living donor has been completed53.  This research shows that “HIV-
infected patients have less knowledge about Living Donor Kidney Transplants (LDKT), 
and there are were more concerns about LDKT, and are less willing to pursue LDKT than 
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those without HIV53.  Moreover, most perceive their HIV status to be a barrier to  
LDKT”53.  Most patients in the study did not want to disclose their HIV status to a 
potential living donor, and felt that this was a barrier53.  Guidelines are inconclusive if 
disclosing HIV status to a potential donor is necessary53.   
A study was done to see what transplant surgeons and transplant nephrologists 
thought about disclosing recipient information to potential living donors40.  The goal of 
the survey study was to determine attitudes about disclosing information to the living 
donor about potential recipient health, health-associated behaviors, and lifestyle 
choices40.  Even though recipient health and behavior does not affect the donor, it may 
influence the donor’s decision making process40.  Overall, both transplant surgeons and 
nephrologists believed one should disclose information about the donor’s health that 
would affect the graft survival and the patient survival, but not information about the 
patient’s lifestyle choices40 .   
There are certain differences between HIV-disease differences between South 
Africa and the United States that may cause US transplant specialists to be weary of HIV-
positive to HIV-positive transplants.  The predominant HIV Subtype in South Africa is 
HIV-1, Group M, Subtype C, which uses chemokine coreceptor R5 (CCR5) throughout 
infection68.  The predominant HIV subtype in the United States it is HIV-1, Group M, 
Subtype B which uses CCR5 coreceptor early in infection and uses coreceptor X4 
(CXCR4) in late infection8,68,.  CCR5 and CXCR4 are coreceptors on CD4 cells for HIV 
entry into the cell8.  Additionally, the transmitted drug resistance in newly infected 
individuals in South Africa is less than 5% while in the United States it is 10-18% 8.  
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However, it is still very rare in the United States for a strain that is resistant to all 
HAART classes to be passed8.  These statistics suggest it is less risky to transplant HIV-
positive organs in South Africa than in the United States, which may affect transplant 
professionals’ opinions.   
Other differences between South Africa and the United States that may affect 
transplant specialists’ beliefs include the transplant waiting list, which is less than 5000 in 
South Africa, but over 100,000 in the United States8.  The number of kidney transplants 
performed in 2013 was 229 in South Africa and 16, 896 in the United States8.  The data 
may suggest that there is both greater number of potential transplants for HIV-positive 
kidney transplants and total renal transplant experience in the United States.   
Transplant specialists may also be weary of theoretical HIV superinfection if the 
recipient receives an organ with a different strain of HIV than they already have8, 15, 20,51.  
HIV superinfection has previously transmitted via IV drug use and sexual contact8.  By 
putting an entire organ into the body, a larger viral inoculum of the second HIV strain is 
introduced and it is unknown if HAART therapy will be able to fight off the new HIV 
strain to stop the superinfection8,20.  It is difficult to assess the strain of HIV during the 
organ procurement process and HIV strain of the donor may not be previously known15.  
One proposed method to decrease risk of superinfection is to only use donors with 
undetectable viral loads51. 
Other concerns may include the quality of the kidneys in HIV-positive donors.  
Will a kidney with HIV-positive status lead to reduction of the allograft survival?  Many 
HIV-positive patients have early kidney abnormalities, as seen by the “high prevalence of 
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early renal dysfunction e.g.  proteinuria, among the HIV-positive population even among 
individuals with normal serum creatinine”8.  Therefore, the transplanted kidney may 
already show early stages of damage8.   
Transplant specialists may also fear the risks of the immunosuppression (IS) 
necessary for kidney transplant.  The incidence of opportunistic infection (OI) after 
kidney transplant in HIV-positive recipients using HIV-negative donors has been 8.6%, 
which is low8.  However, there is increased risk with using HIV-positive organs that must 
be closely monitored20.  Additionally, there has been 2-4x increased incidence of 
immunologic rejection of all donations in HIV-positive recipients for unclear reasons20.  
Potential mechanisms to the rejection include specific HAART drug reactions with IS or 
the underlying immunocompromised state caused by HIV infection20. 
The guidelines and protocols set forth by the HOPE act criteria were created in a 
way to minimize all of these risks.  At first, all HIV-positive to HIV-positive transplants 
must be done in a clinical research setting20, 22.  This setting ensures many safety and 
protective components for patients 20.  Additionally, the National Institute of Health 
guidelines require minimum outcome data, specific inclusion criteria, and minimum prior 
experience for the transplant center20.  Moreover, patients will undergo a formal consent 
process20 acknowledging that they understand the process is unproven in the United 
States, ensuring that the patient is well informed.   
There is also the risk that HIV-positive organs will inadvertently be transplanted 
into an HIV-negative patient20 .  However, this has not happened in analogous settings, 
such as HCV organs being accidentally transplanted into HCV-negative patients20.  
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Hospitals also have experience with taking precautions and enforcing proper protocols 
with ABO compatibility56.  Additionally, there are protocols written into the HOPE act to 
ensure this will not take place47, 56.  The law requires that “each transplant hospital shall 
have an institutional biohazard plan for handling of HIV-positive organs… that is 
designed to prevent and/or manage inadvertent transmission of or exposure to HIV”56.  
Therefore, the transplantation of HIV positive organs should not put others at risk of HIV 
transmission.   
With all the risks that are inherent with HIV-positive donors to HIV-positive 
recipients, one may ask ‘why venture there in the first place?’ The problem includes the 
mismatch between supply and demand for organs, and the waste of HIV-positive organs 
that occurs if these organs could be used successfully for transplantation but are not9.  
The ability to choose between receiving an HIV-positive organ when one is offered and 
waiting potentially years to receive a HIV-negative organ would likely alter one’s life 
expectancy.  As previously discussed, waitlist mortality is increased for HIV-positive 
patients compared to HIV-negative patients8, 9, 20.  Trials have been successful elsewhere 
in the world, thus it is time for these transplants to help patients in the United States.  The 
controlled clinical trial environment in which the first HIV-positive to HIV-positive 
transplants will be done to allow for precise scientific monitoring that will benefit both 
the patients in the trial and future patients.   
Since April 3, 1933, when Yurii Voronoy completed the first human kidney 
allotranspant39, transplantation has been a science that pushed the boundaries of 
medicine22.  Transplant specialists inherently want to continue to push that boundary, and 
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are likely to accept HIV-positive donor organs to HIV-positive transplant recipients as 
the next frontier in transplant science.   
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METHODS 
Study design 
This study will be an electronic mail survey sent to transplant surgeons, transplant 
nephrologists, and transplant physician assistants and seek to obtain their opinions on 
HIV-positive donor organs to HIV-positive organ transplant recipients.  The study will 
then include a qualitative and quantitative analysis of the survey results.   
 
Study population and sampling 
The study population is all transplant surgeons, transplant nephrologists, and transplant 
surgical physician assistants in the United States.  There are 208 transplant surgeons60 
and 9651 nephrologists60 in the United States, as well as 94,400 PAs in the United 
States11. Of the PAs, 27% practice in surgery or a surgical subspecialty1 and 56 of 15,925 
(0.35%) respondents to a national PA survey identify their specialty as transplant 
surgery1.  The contact information for the intended study participants will be obtained via 
the American Society of Transplantation (AST), American Society of Transplant 
Surgeons (ASTS), and American Association of Surgical Physician Assistants (AASPA) 
mailing lists.  Study inclusion criteria is participation in at least 15 transplant surgeries 
within the past 12 months.  Exclusion criteria include self-identification as retired or 
inactive, unwilling to complete the survey, or more than 3 questions on the survey left 
unanswered.   
Surveys will be sent to each identified person in order to maximize the number of 
results because health care providers typically have low response rates to surveys.  
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Intervention 
In the Winter of 2017, the American Society of Transplantation (AST), American Society 
of Transplant Surgeons (ASTS), and American Association of Surgical Physician 
Assistants (AASPA) mailing lists will be rented.   
At the same time, the Presidents of these three associations will be contacted 
about the purpose of the study to see if they will be willing to forward the email with 
survey link to members of their associations 
In the Spring of 2017, each of the identified transplant surgeons, transplant 
nephrologists, and surgical physician assistants will be sent a personalized pre-survey 
notification of the study.  This email will be sent to them from the president of the 
association from which their contact information was obtained in order to increase 
participation rates.  This pre-survey email will explain the purpose of the study on Boston 
University letterhead.  A copy of the pre-survey email can be found in Appendix A.   
Two weeks later an email with a link to the survey will be emailed to each 
identified subject from the president of the association.  The body of the email will 
include the Boston University logo and the text will explain the purpose of the study.  An 
example of the email text can be found in Appendix B and a copy of the survey can be 
found in Appendix C.   
After 1, 2, and 3 weeks, if there is no response to the survey the reminder emails 
will be sent that include the link to the survey.   
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Study variables and measures 
The survey will include two sections- one on the respondent’s demographics and one on 
their perceptions.   
Demographics: 
• Age (decade) 
• Gender 
• OPTN Region 
• Professional Role 
• Years in Practice 
• Number of transplants they participated in within the last year 
• Number of HIV-positive transplants they participated in within the past year 
Perceptions: 
• If they are aware that HIV-positive to HIV-positive organ transplants are legal 
• If they think HIV-positive to HIV-positive transplants will be successful 
• If they think HIV-positive patients will agree to receive HIV-positive organs 
• Thoughts on HIV-positive living donors 
• Concerns, limitations or obstacles 
• Overall feelings 
Recruitment 
The subjects will include all US transplant surgeons, transplant nephrologists, and 
transplant PAs in the mailing lists of the American Society of Transplant Surgeons, the 
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American Society of Transplantation, and American Association of Surgical Physician 
Assistants, as of January 1, 2017.  The physicians and any PAs on the AST and ASTS 
lists will be contacted.  Because there is no specific organization that targets PAs who 
participate in transplants, the AASPA list will ensure transplant PAs are reached, and the 
inclusion/exclusion criteria will emit PAs who are on the AASPA mailing list but are 
inappropriate for the study.  It is expected that the AASPA list will generate many names 
that are excluded.  If an email address appears on more than one organization mailing list, 
only one email will be sent.  From these lists, everyone who has not participated in 
transplant surgeries within the past year or who self-identifies as retired or non-active 
will be excluded.   
 
Data collection 
The data will be collected as electronic surveys using Qualtrics software. Perception 
questions will appear first, followed by demographic questions.  Perception questions 
types will include ranking on a scale from 1-5, multiple choice with multiple responses 
allowed, and open-ended response.  Demographic questions will be multiple choice 
responses.  A copy of the survey can be found in Appendix C.   
 
Data analysis 
The data obtained from the surveys will be reviewed and analyzed.  Overall perceptions 
of transplant specialists will be determined.  Questionnaire items that were in agree-
disagree form will be converted into a numerical score for analysis using the Likert scale.  
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Question 1 is for consent and will not be analyzed.  Any respondent that answers “no” 
will have all of their responses removed from the data pool.   
Questions 2-9 measure respondents’ perceptions.  Questions 2-6 are based on 
Likert Scales.  For each question, the mean and standard deviation will be calculated, 
with 3.0 considered neutral.  Question 7 has multiple choices in which the respondent 
may choose one, without write-in options.  This question will be analyzed using 
proportions.  Question 8 has multiple answer selections as well as fill-in-the-blank 
responses, and therefore will be analyzed by raw counts.  Question 9 allows for a write in 
answer only.  Qualtrics software will be utilized to determine themes.   
Questions 10 – 17 gather demographic data and all will be analyzed as 
proportions.  Questions 18 and 19 are follow ups to question 17, depending on whether 
yes or no is selected in question 17.  If yes is selected in question 17, the respondent sees 
question 18.  If no is selected in question 17, the respondent sees question 19.  Question 
18 is a fill-in question.  Responses will be analyzed as raw counts and proportions.  
Question 19 has dichotomous data.  It will be analyzed as both means and proportions.   
After each question is analyzed individually, certain questions will be correlated.  
Questions 2-5 will be analyzed using demographic information.  For each question, 
Mann-Whitney U test will be used to analyze the effect of gender on the response 
(Question 10) as well as the effect of participation on a HIV-positive case in the past year 
on response (Question 17).  One-way analysis of variance (ANOVA) will be completed 
for age, professional role, years in practice, OPTN region, primary organs transplanted, 
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and transplants within the past year to determine if there are significant differences.  
Questions 6-9 will also be examined with demographic data via ANOVA. 
Additionally, all data would be read through looking for nascent themes and 
would be categorized based on themes.   
 
Timeline and resources 
Fall 2016 
• Create survey, pre-survey email 
• Obtain contact information for participants 
• IRB submission and approval 
Spring 2017 
• Send pre-survey email  
• Send surveys via email 
• Send survey reminders via email 
• Obtain results 
Summer and Fall 2017 
• Analysis of results 
• Manuscript submission  
Additional resources needed: 
• Qualtrics software  
• Statistician  
• Fees for Mailing Lists 
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Institutional Review Board 
This study will be submitted to the Boston University Medical Campus Institutional 
Review Board for expedited review.  This survey meets criteria for expedited review for 
“research on individual or group characteristics or behavior or research employing 
survey, interview, oral history, focus group, program evaluation, human factors 
evaluation, or quality assurance”.  The pre-survey email and the text of the email will 
both include a consent statement to ask the participants’ approval to be involved in 
research.  Furthermore, Qualtrics is an IRB approved software.  The study invokes 
minimal risk to its participants, is not misleading or deceiving, does not involve sensitive 
populations, or involve intrusive or stressful procedures.  If the IRB does not approve the 
study for expedited review, the study will be submitted for full review.   
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CONCLUSION 
Discussion 
HIV-positive donor to HIV-positive recipient transplants were made legal in 2013 in the 
United States when the HOPE Act was passed, and the first HIV-positive donor to HIV-
positive recipient transplant was completed in March 2016.  To date, there has been no 
study that has assessed at the attitudes of the medical community involved in these 
transplants.  This study is unique in that it attempts to obtain the perceptions and concerns 
the transplant specialists have about HIV-positive donor organs to HIV-positive 
transplant recipients. 
 There are limitations to this study that should be pointed out.  First, survey studies 
in the medical community traditionally have a very low response rate.  If there are too 
few responses, the data will not have enough power to draw any significant conclusions.  
Attempts to increase the response rate include sending a pre-survey email, having the 
President of the organization forward the emails, and inclusion of the Boston University 
letterhead throughout study materials.  Additionally, because the survey will be sent out 
via email it is likely that some intended participants will have not receive the survey due 
to their email settings or a changed their email address.  Other limitations include that 
respondents may feel uncomfortable responding with their true perception, and therefore 
provide untruthful answers.  Furthermore, people may not choose the extremes on the 
Likert scale even if that is where their perception lays.   
 As HIV-positive to HIV-positive organ transplants become legal in more 
countries, similar surveys can be conducted in those regions.  While this study will be a 
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good representation for transplant professionals in the United States, it should not be 
generalized to other countries.  It would be interesting to compare perceptions between 
United States transplant professionals and those from other countries.  Furthermore, it 
will be interesting to repeat the study when HIV-positive to HIV-positive organ 
transplants are no longer in clinical trial phases to analyze how perceptions have changed 
over time in the United States.   
 
Summary 
Kidney transplants have been proven to be the best choice of renal replacement therapy 
for most people with ESRD and appears to be similar for HIV-positive patients who have 
renal failure.  Studies in South Africa show that using HIV-positive organ donors for 
HIV-positive recipients have high success rates.  These transplants were made legal in the 
United States in 2013 when the HOPE Act was passed, and the first HIV-positive organ 
transplant was completed in March 2016 with good results.  It is likely that transplant 
surgeons, nephrologists and transplant surgical physician assistants will welcome HIV-
positive donor organs to HIV-positive transplants as an advancement in the field of 
transplant sciences, and expect these transplants to be a good treatment option for patients 
within the next five to ten years. 
 The proposed study will look to understand the opinions of transplant surgeons, 
transplant nephrologists and transplant physician assistants concerning HIV-positive to 
HIV-positive organ transplants.  There has been no study to date that has gathered 
perceptions on this topic in the United States. 
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Public health significance 
Gathering the opinions of transplant surgeons, transplant nephrologists and surgical PAs 
regarding HIV-positive to HIV-positive organ transplants at the beginning of this era has 
substantial public health applications.  First, understanding these perceptions at a time 
when very few of these transplants have been completed in the United States sets a 
foundation for future researchers in which to compare.  Additionally, determining if there 
are variations in opinions based on the demographic stratification will assist in our 
analysis of any potential demographical differences that can affect care for HIV-positive 
organ recipient failure or survival.  For example, the survey can reveal regional 
differences in HIV-positive patient access to surgical teams willing to transplant HIV-
positive organs.  Furthermore, understanding the concerns of the transplant specialists 
can help determine where funding for further studies can be allocated.  Therefore, the 
public health implications of this survey study may be significant.   
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APPENDIX A 
Pre-survey email 
 
Dear ____________, 
As the transplant community continues to expand our collective knowledge, it’s 
important to collect information on what our colleagues perceive about these 
advancements.  On February 1st, 2017, you will receive an email with a survey link 
giving you the opportunity to share your perspective on one of the newest advancements 
in our field: HIV-positive organ donations to HIV-positive recipient transplants.   
The purpose of this survey is to obtain your opinions on HIV-positive to HIV-positive 
transplants at the beginning of this era.  The survey measures opinions and perceptions, 
there are no right or wrong answers.  We will also be asking questions about your 
demographics.  There are no mandatory questions and feel free to leave any questions 
unanswered that you wish to.  All of your responses will be kept confidential. 
This is a research study conducted by Boston University researchers.  We anticipate it 
taking less than 15 minutes to complete.  The survey is completely voluntary and a 
decision to not participate will not affect you in any way.  If you would prefer to not 
receive the survey, please contact us and we would be happy to take your email off of our 
mailing list.  If you have questions about your rights as a research subject, please contact 
Boston University IRB at 617-638-7207 or medirb@bu.edu .   
Thank you in advance for your time in February when you receive the survey.   
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Appendix B 
Survey Email, email body text 
Dear ____________, 
 
A few weeks ago, you were sent a pre-notification of a survey about HIV-positive organ 
donations to HIV-positive transplant recipient.  Please click the link below or copy and 
paste into your browser to complete the survey.  By clicking the link and taking the 
survey, you are consenting to being a research subject in this study. 
https://bostonu.qualtrics.com/SE/?SID=SV_2cceHafj4ZLPtMF 
The purpose of this survey is to obtain your opinions on HIV-positive to HIV-positive 
transplants at the beginning of this era.  The survey measures opinions and perceptions, 
there are no right or wrong answers.  We will also be asking questions about your 
demographics.  There are no mandatory questions and feel free to leave any questions 
unanswered that you wish to.  All of your responses will be kept confidential. 
This is a research study conducted by Boston University researchers.  We anticipate it 
taking less than 15 minutes to complete.  The survey is completely voluntary and a 
decision to not participate will not affect you in any way.  If you would prefer to not take 
the survey, please contact us and we would be happy to take your email off of our list so 
you will not receive any reminder emails.  If you have questions about your rights as a 
research subject, please contact Boston University IRB at 617-638-7207 or 
medirb@bu.edu .   
Thank you in advance for your time.  
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Appendix C 
Survey for Transplant Professionals 
 
Q1) You are invited to take part in a research survey about HIV-positive donor to HIV-
positive recipient organ transplants.  Your participation will require approximately 15 
minutes and is completed online at your computer.  There are no known risks or 
discomforts associated with this survey.  Taking part in this study is completely 
voluntary.  If you choose to be in the study you can withdraw at any time without 
adversely affecting your relationship with anyone at Boston University.  Your responses 
will be kept strictly confidential, and digital data will be stored in secure computer files.  
Any report of this research that is made available to the public will not include your name 
or any other individual information by which you could be identified.  Please feel free to 
print a copy of this consent page to keep for your records.  Clicking the “Next” button 
below indicates that you are 18 years of age or older, and indicates your consent to 
participate in this survey.  Clicking the "Close" button will close the survey. 
• Next  
• Close  
 
Q2) Are you aware that HIV-positive organs are now able to be transplanted into HIV-
positive patients in the United States as part of clinical research trials? 
• Yes  
• No  
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Q3) To what extent do you agree/disagree with the following statement:  Within the next 
5-10 years, HIV-positive to HIV-positive organ transplants will be a safe and effective 
treatment option, with success rates similar to non-HIV infected donor organs. 
• Strongly agree  
• Somewhat agree  
• Neither agree nor disagree  
• Somewhat disagree  
• Strongly disagree  
 
Q4) To what extent do you agree/disagree with the following statement:  After 
appropriate counseling, most of my HIV-positive patients will agree to accept an HIV-
positive organ if one became available instead of remaining on the organ donor waiting 
list. 
• Strongly agree  
• Somewhat agree  
• Neither agree nor disagree  
• Somewhat disagree  
• Strongly disagree  
 
Q5) I believe that there are ethical considerations concerning HIV-positive to HIV-
positive organ transplants that the community needs to address. 
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• Strongly agree  
• Somewhat agree  
• Neither agree nor disagree  
• Somewhat disagree  
• Strongly disagree  
 
Q6) I am willing to participate in HIV-positive to HIV-positive organ transplants in my 
professional role. 
• Strongly agree  
• Somewhat agree  
• Neither agree nor disagree  
• Somewhat disagree  
• Strongly disagree  
 
Q7) I believe that clinical research trials using HIV-positive organs should continue 
• Yes, using deceased donors only  
• Yes, using living donors only  
• Yes, using both deceased and living donors  
• No, I do not think HIV-positive organs should be used in transplants, even in 
clinical trials. 
 
Q8) My concerns about HIV-positive to HIV-positive organ transplants include: 
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• Lack of demonstrated success  
• Interactions of immunosuppressant therapy and HAART therapy  
• Risk of superinfection  
• Increased harm to patient 
• Increased need for re-transplant  
• Increased complexity of transplant surgery itself  
• Safety of my transplant staff  
• Other: ____________________ 
• None of the above  
 
Q9) Overall, my feelings about HIV-positive to HIV-positive organ transplants can be 
summarized as: 
 
Q10) Sex: 
• Male  
• Female  
• Other 
• Prefer not to say  
 
Q11) Age: 
• 20-30  
• 31-40  
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• 41-50  
• 51-60  
• 61-70  
• 71-80  
• 81+  
 
Q12) What is your professional role? 
• Transplant surgeon  
• Transplant Nephrologist 
• Transplant Coordinator 
• Transplant physician assistant/nurse practitioner 
• Other ____________________ 
 
Q13) How many years have you been in practice? 
• Less than 5  
• 6-10  
• 11-15  
• 16-20  
• 21-25  
• >25  
 
Q14) What OPTN region do you practice in? 
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Q15) What organ(s) do you primarily transplant? 
 
Q16) Approximately how many transplants did you participate in within the past 12 
months? 
• <10  
• 10-25  
• 25-50  
• 50-75  
• 75-100  
• >100  
 
Q17) Did you participate in the transplantation of any organ into any HIV-positive 
patients within the past 12 months? 
• Yes  
• No  
• I don't remember  
 
Answer) If, Did you participate in the transplanting an organ into any HIV-positive 
patients within the past 12 months? Yes Is Selected 
Q18 Approximately how many HIV-positive organ transplants did you participate 
in within the past 12 months? 
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Answer) If, Did you participate in the transplanting an organ into any HIV-positive 
patients within the past 12 months? Yes Is Not Selected 
Q19 Are HIV-positive patients considered contraindicated to transplantation at 
your center? 
• Yes  
• No  
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